Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines

NCT01765413 | Completed

• 1 other identifier: CRC305A
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

It is thought that vaccines trigger innate inflammatory responses to induce antigenspecific adaptive immunity (the desired effect), but excessive inflammation may lead to serious inflammatory complications or unwanted side effects. Currently there is a lack of reliable biomarkers (a measurable biological response that predicts something) able to predict severe inflammation and this has resulted in the development of several vaccines being terminated and the withdrawal of some licensed vaccines which were associated with inflammatory complications. This study is part of the BIOVACSAFE project which is a 5year €30M project funded by the Innovative Medicine Initiative. The project involves a series of clinical studies using licensed vaccines as benchmarks to generate clinical data on inflammation and identify biomarkers that can be used to predict acceptable reactogenicity. The target is to identify biomarkers that can predict the occurrence of beneficial and detrimental effects in response to a vaccine. Such biomarkers could be used in future vaccine development programs to optimize selection of vaccine candidates with a profile that will be unlikely to generate worrisome safety signals once they are in generalized use. This study is one in a series of "training" studies which will each use different licensed vaccines that are prototypical representatives of a class of vaccine used in a particular target population. Forty eight subjects will be randomised into three groups to receive: A) Varicella zoster vaccine (n = 20), B) Yellow Fever vaccine (n = 20), C) Saline placebo (n = 8). Following a screening visit, participants will undergo a seven day residential visit which will include immunization and intensive monitoring of physiological (e.g. heart rate, oral temperature, blood pressure) metabolic and immune (innate and adaptive) parameters. This visit will be followed up by four outpatient visits with further monitoring and blood samples.

Conditions

Healthy

Keywords

To identify; biomarkers; of vaccine safety; Volunteers

Outcome Measures

Primary Outcomes (1)

• Change from baseline values of global gene expression in whole blood.

  Visits 1 (Day -28 to -2), 2 (Day -1 to +5) , 3 (Day 7), 4 Day 14), 5 (Day 21) and 6 (Day 28).

Other Outcomes (3)

• Proportion of subjects experiencing vaccine-related clinical events following administration of first dose of vaccine.

  Visits 2 (Day -1 to +5) , 3 (Day 7), 4 Day 14), 5 (Day 21) and 6 (Day 28).

• Change from baseline values of copy number of yellow fever virus in plasma.

  Visits 2 (Day -1 to +5) , 3 (Day 7), 4 Day 14), 5 (Day 21) and 6 (Day 28).

• Change from baseline values in concentration of serum anti-yellow fever antibodies.

  Visits 1 (Day -28 to -2), 2 (Day -1 to +5) , 3 (Day 7), 4 Day 14), 5 (Day 21) and 6 (Day 28).

Study Arms (3)

Varilrix

EXPERIMENTAL

Participants receive one dose of 'Varilrix' varicella-zoster vaccine.

Biological: Varicella-zoster virus

Stamaril

EXPERIMENTAL

Participants receive one dose of 'Stamaril' yellow fever vaccine.

Biological: Yellow Fever Vaccine

Placebo

PLACEBO COMPARATOR

Participants receive one injection of placebo.

Biological: Placebo

Interventions

Varicella-zoster virus BIOLOGICAL

Also known as: Varilrix

Varilrix

Yellow Fever Vaccine BIOLOGICAL

Also known as: Stamaril

Stamaril

Placebo BIOLOGICAL

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female subjects aged 18-45years inclusive.
• The subject is, in the opinion of the investigator, healthy on the basis of medical history, vital signs, \& the results of routine laboratory tests with no active disease process that could interfere with the study endpoints.
• Body Mass Index ≥18.5 and \<29.5
• The subject is able to read \& understand the ICF, \& understand study procedures.
• The subject has signed the ICF.
• Subjects must fulfill the immune status eligibility only for the group they are allocated to::
• To be eligible for the Varilrix group the subject must be immune to varicella zoster confirmed on screening by a varicella zoster serum antibody titre by ELISA test (cut-off: 25 mIU/mL)
• To be eligible for the Stamaril group the subject must be seronegative to flaviviruses as confirmed by ELISA test with a predetermined cut-off
• Available for followup for the duration of the study.
• Agree to abstain from donating blood during \& for three months after the end of their participation in the study, or longer if necessary.
• If heterosexually active female, willing to use an effective method of contraception with partner from 30 days prior to, \& 3 months after, vaccination. Willing to undergo urine pregnancy tests prior to vaccination \& blood pregnancy test at screening \& final follow up.
• The subject has venous access sufficient to allow blood sampling as per protocol.

You may not qualify if:

• Significant dietary restrictions (e.g. vegan, lactose intolerant, but vegetarian acceptable) or life threatening food allergies (e.g. anaphylaxis related nut allergies).
• Pregnant or lactating at any point during the study from screening to final follow up.
• Subjects must fulfill the vaccine contraindications eligibility only for the group they are allocated to:
• a.For group A (Varilrix) - i.History of hypersensitivity to neomycin (other than contact dermatitis), any of the excipients in the vaccine (amino acids, human albumin, lactose, mannitol, sorbitol) or to any other varicella vaccine.
• ii.Known hypersensitivity to a first dose of Varilrix.
• b.For group B (Stamaril) - i.Previous receipt of a yellow fever vaccine ii.History of hypersensitivity to eggs, chicken proteins or any component of Stamaril (Lactose, Sorbitol E420, L-histidine hydrochloride, L-alanine, Sodium chloride, Potassium chloride, Disodium phosphate, Monopotassium phosphate, Calcium chloride, Magnesium sulphate)
• Presence of primary or acquired immunodeficiency states with a total lymphocyte count less than 1,200 per mm3 or presenting other evidence of lack of cellular immune competence e.g. leukaemias, lymphomas, blood dyscrasias, or patients receiving immunosuppressive therapy (including regular use of oral, inhaled, topical or parenteral corticosteroids).
• Use of any immune suppressing or immunomodulating drugs within 6 months of Visit 1
• Regular use of nonsteroidal anti-inflammatory drugs (by any route of administration including topical) within 6 months of Visit 1 (screening) considered by the study physician as likely to interfere with immune responses.
• Receipt of a vaccine within 30 days of visit 2, or requirement to receive another vaccine within the study period.
• Presence of an acute severe febrile illness at time of immunization.
• History of alcohol, narcotic, benzodiazepine, or other substance abuse or dependence within the 12 months preceding Visit 1.
• Currently participating in another clinical study with an investigational or non-investigational drug or device, or has participated in a clinical trial within the 3 months preceding Visit 1.
• Any condition that, in the investigator's opinion, compromises the subject's ability to meet protocol requirements or to complete the study.
• Receipt of blood products or immunoglobin, or blood donation, within 3 months of screening.

Sponsors & Collaborators

• University of Surrey: lead
• Innovative Medicines Initiative: collaborator
• GlaxoSmithKline: collaborator
• Sanofi Pasteur, a Sanofi Company: collaborator

Study Sites (1)

University of Surrey, (Surrey Clinical Research Centre)

Guildford, Surrey, GU2 7XP, United Kingdom

Location

Related Publications (2)

• Weiner J, Lewis DJM, Maertzdorf J, Mollenkopf HJ, Bodinham C, Pizzoferro K, Linley C, Greenwood A, Mantovani A, Bottazzi B, Denoel P, Leroux-Roels G, Kester KE, Jonsdottir I, van den Berg R, Kaufmann SHE, Del Giudice G. Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium. Sci Rep. 2019 Dec 30;9(1):20362. doi: 10.1038/s41598-019-56994-8.

  PMID: 31889148 DERIVED

• Muturi-Kioi V, Lewis D, Launay O, Leroux-Roels G, Anemona A, Loulergue P, Bodinham CL, Aerssens A, Groth N, Saul A, Podda A. Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. PLoS One. 2016 Aug 4;11(8):e0157385. doi: 10.1371/journal.pone.0157385. eCollection 2016.

  PMID: 27490698 DERIVED

MeSH Terms

Interventions

Yellow Fever Vaccine

Intervention Hierarchy (Ancestors)

Viral Vaccines; Vaccines; Biological Products; Complex Mixtures

Study Officials

• David J Lewis

  University of Surrey

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 15, 2012
• First Posted: January 10, 2013
• Study Start: September 1, 2013
• Primary Completion: January 1, 2014
• Study Completion: January 1, 2014
• Last Updated: February 16, 2015

Record last verified: 2013-09

Locations

GB (1)